Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001564590-20-005888
Filing Date
2020-02-24
Accepted
2020-02-24 07:34:23
Documents
84
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 10-K agle-10k_20191231.htm 10-K 3300914
2 EX-4.5 agle-ex45_732.htm EX-4.5 44886
3 EX-21.1 agle-ex211_888.htm EX-21.1 13520
4 EX-23.1 agle-ex231_12.htm EX-23.1 2104
5 EX-31.1 agle-ex311_11.htm EX-31.1 15952
6 EX-31.2 agle-ex312_14.htm EX-31.2 15489
7 EX-32.1 agle-ex321_13.htm EX-32.1 6781
8 EX-32.2 agle-ex322_6.htm EX-32.2 6752
9 GRAPHIC g2kawa3ldanj000001.jpg GRAPHIC 28766
10 GRAPHIC g2kawa3ldanj000002.jpg GRAPHIC 27976
  Complete submission text file 0001564590-20-005888.txt   10241246

Data Files

Seq Description Document Type Size
11 XBRL INSTANCE DOCUMENT agle-20191231.xml EX-101.INS 2168928
12 XBRL TAXONOMY EXTENSION SCHEMA agle-20191231.xsd EX-101.SCH 62599
13 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE agle-20191231_cal.xml EX-101.CAL 67581
14 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE agle-20191231_def.xml EX-101.DEF 195634
15 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20191231_lab.xml EX-101.LAB 509145
16 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20191231_pre.xml EX-101.PRE 385326
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37722 | Film No.: 20642063
SIC: 2834 Pharmaceutical Preparations